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Possible 
Transmission of 
Pandemic (HIN1) 
2009 Virus with 
Oseltamivir 
Resistance 
To the Editor: In March 2009, 
a new strain of inﬂ  uenza A (H1N1) 
virus of swine origin emerged; the vi-
rus had crossed the species barrier to 
humans and acquired the capability of 
human-to-human transmission. Soon 
after, the World Health Organization 
raised the worldwide pandemic alert 
to level 6 (www.who.int/en), declar-
ing the ﬁ  rst inﬂ  uenza pandemic in the 
past 42 years. The virus was named 
inﬂ   uenza A pandemic (H1N1) 2009 
virus. The illness caused by this virus 
is particularly dangerous for pregnant 
women and for patients with chronic 
diseases (1). The preferred treatment 
is a neuraminidase inhibitor, zanami-
vir or oseltamivir (2).
Around the world, several dozen 
cases of resistance to oseltamivir in 
persons with or without exposure to 
the drug have been reported (3). How-
ever, only limited information is avail-
able with regard to initial infections 
with oseltamivir-resistant viruses (4). 
We report a case of possible human-
to-human transmission of pandemic 
(H1N1) 2009 virus in Israel.
After the recent discovery of 
oseltamivir-resistant strains, we con-
ducted a retrospective study of osel-
tamivir-resistance mutations in viral 
RNA ampliﬁ  ed from specimens from 
patients hospitalized >1 week with 
pandemic (H1N1) 2009. All samples 
were ﬁ  rst tested for the H275Y mu-
tation by using an in-house real-time 
reverse transcription–PCR (RT-PCR) 
assay developed at the Central Vi-
rology Laboratory of Chaim Sheba 
Medical Center; positive results were 
conﬁ  rmed by sequencing. The histi-
dine-to-tyrosine mutation at the 275 
position of the neuraminidase protein 
results in reduced binding of oselta-
mivir.
During June–August 2009, ≈80 
children in an institution for disabled 
children were suspected of being in-
fected with pandemic (H1N1) 2009 
virus. The children had inﬂ  uenza-like 
signs and symptoms, and at that time 
the only inﬂ  uenza virus circulating in 
Israel was pandemic (H1N1) virus. Of 
these 80 patients, 10 were hospitalized 
because of the severity of their clinical 
signs or disease complications, and for 
7, RNA of the pandemic (H1N1) 2009 
virus was detected in throat and nasal 
swabs by real-time RT-PCR.
Patient 1 was a 13-year-old boy 
with cerebral palsy and partial blind-
ness, who was treated with oseltamivir 
(60 mg twice a day) for 5 days (July 
27–31, 2009). After some improve-
ment, his condition worsened, and 
he was hospitalized on August 13 for 
breathing difﬁ   culty and high fever. 
Real-time RT-PCR indicated infection 
with pandemic (H1N1) 2009 virus. 
During our survey, we found that pa-
tient 1 was infected with a virus car-
rying the H275Y mutation, suggesting 
that the mutation evolved during osel-
tamivir treatment.
Patient 2 was a 10-year-old girl 
who had lived in the room next to 
patient 1 and who also had cerebral 
palsy. Her signs and symptoms start-
ed on August 13, 2009, and she was 
hospitalized on August 15. She was 
treated in the hospital for 5 consecu-
tive days with oseltamivir, steroids, 
and augmentin; she was discharged on 
August 21. Her diagnosis was made 
early in the clinical course of her in-
fection, and she was infected with 
pandemic (H1N1) 2009 virus carrying 
the H275Y mutation.
In contrast, none of the other 8 
children who were hospitalized for 
pandemic (H1N1) 2009 carried the 
mutation. Although we cannot rule out 
the possibility that the virus was trans-
mitted by a third person, we suggest 
that the virus carrying the resistance 
mutation was probably transmitted 
from patient 1 to patient 2. This trans-
mission is probable because these 2 
patients lived in adjacent rooms, they 
were in contact with each other, clini-
cal onset of patient 1 preceded that of 
patient 2 by a few days, and patient 2 
had the mutation at the beginning of 
her disease.
Fortunately, despite the condi-
tions that favor virus spread in such 
institutions, this virus did not seem to 
spread further; the other 8 hospitalized 
children from this institution were in-
fected with the wild-type virus. Nev-
ertheless, the potential for spread of 
pandemic (H1N1) 2009 virus carrying 
the oseltamivir resistance mutation 
exists, thereby emphasizing the urgent 
need for a vaccination to prevent ill-
ness and for alternative drugs to treat 
infected patients.
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Cross-Reactive 
Antibodies to 
Pandemic (H1N1) 
2009 Virus, 
Singapore 
To the Editor: Accumulating 
evidence suggests that the degree 
of serologic cross-reactivity to pan-
demic (H1N1) 2009 virus varies be-
tween populations worldwide. To 
assess potential serologic cross-reac-
tivity in Singapore, we obtained se-
rum samples during May–June 2009 
from 50 randomly recruited, healthy 
volunteers born mostly before 1958 
(i.e., potentially those with some 
natural exposure to the then circulat-
ing H1N1/1918-like subtype viruses) 
before widespread transmission of 
pandemic (H1N1) 2009 virus in Sin-
gapore. Standard serologic hemagglu-
tination-inhibition (HI) tests (1) were 
performed in 2 reference laboratories 
(Singapore during July–October 2009 
and Melbourne, Australia, in January 
2010), and microneutralization (MN) 
tests (2) were performed in 1 reference 
laboratory (Singapore) for each serum 
sample against pandemic (H1N1) 
2009 virus (A/Auckland/1/2009) and 
seasonal inﬂ  uenza (H1N1) virus (A/
Brisbane/59/2007). The study was re-
viewed and approved by the National 
Healthcare Group Domain-Speciﬁ  c 
Review Board (ref no. E/09/289, 
J.W.T. principal investigator).
Mean ± SD age of participants 
was 60.1 ± 7.4 years (range 45–82 
years); 31 (62%) were women, 42 
(84%) were born in Singapore (the rest 
in Hong Kong, Malaysia, or India), 
and 26 (52%) had not traveled outside 
Singapore. None of the 50 partici-
pants had HI or MN titers >40 against 
inﬂ  uenza  A/Auckland/1/2009  when 
samples were tested in either labora-
tory. In contrast, 18 samples had either 
HI or MN titers >40 against seasonal 
inﬂ  uenza A/Brisbane/59/2007 (Table). 
Use of guinea pig or turkey erythro-
cytes in HI assays had little effect on 
the results (Table). Thus, our results 
are similar to those of Chen et al. (3) 
and Itoh et al. (4) for this small cohort 
in that none of the participants 40–80 
years of age from Southeast Asia had 
cross-reactive antibodies to pandemic 
(H1N1) 2009 virus.
Although differences in popu-
lation demographics and laboratory 
methods used make comparisons 
between studies difﬁ  cult, one of the 
most striking observations from vari-
ous studies has been the higher levels 
of cross-reactive antibody titers in pre-
pandemic serum samples from older 
persons (>80 years of age) in western 
populations (United States and United 
Kingdom) (5,6) than from persons  in 
eastern populations (China) (3) and 
Singapore (this study). Although Itoh 
et al (4) did not ﬁ  nd serologic cross-
reactivity in the population <80 years 
of age in Japan, they found higher 
levels of cross-reactive antibodies in 
their population >80 years of age. His-
torically, because epidemiologic data 
suggest that inﬂ  uenza (H1N1)/1918–
like viruses were widespread in Asia, 
these contrasting results are a stimulus 
for additional large-scale studies to as-
sess the effect of these viruses in these 
populations.   
Although the main limitation of 
our study is the small sample size, 
several reasons may account for dif-
ferent  ﬁ  ndings in population studies 
of serologic cross-reactivity. First, 
populations may not be comparable 
in terms of geographic proximity and 
their potential for community-ac-
quired infection within the same wave 
of a seasonal inﬂ  uenza epidemic with 
a virus that was similar to pandemic 
(H1N1) 2009 virus. Chen et al. (3) re-
ported that their serum samples were 
obtained mainly from rural farmers 
in China who lived farther apart than 
city dwellers, However, Hancock et 
al. (5) reported that their samples were 
obtained from vaccine trials conduct-
ed in 1976 or 2005–2009 involving 
academic, government, and industrial 
workers, which likely indicates that 
these persons were urban-based (i.e., 
living and working more closely to 
each other than rural farmers in Chi-
na). Thus, results of our study may 
not be directly comparable with either 
of these previous studies because our 
population resided in Southeast Asia 
and was urban-based.
Second, use of seasonal inﬂ  uenza 
vaccine has varied in different popula-
tions, with Singapore having one of the 
lowest recorded use rates in the West-
ern Paciﬁ  c region, and far lower than 
that in the United States (6). If previ-
ous seasonal inﬂ  uenza viruses shared 
a degree of antigenic cross-reactivity 
with pandemic (H1N1) 2009 virus, 
contemporary seasonal inﬂ  uenza vac-
cines, if well-matched, should reﬂ  ect 
changing antigenicity of seasonal 
inﬂ   uenza viruses; thus, vaccinated 
populations may have acquired some 
serologic cross-reactivity through pre-
vious inﬂ  uenza vaccines. However, it 
is likely that past infection rather than 
vaccination results in cross-reactivity, 
as suggested by Miller et al. (7).
Third, because pandemic (H1N1) 
2009 virus originated mainly from 
swine viruses in North America and 
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